DE69942837D1 - Systemisches virus/ligand genabgabemittel und gentherapie - Google Patents

Systemisches virus/ligand genabgabemittel und gentherapie

Info

Publication number
DE69942837D1
DE69942837D1 DE69942837T DE69942837T DE69942837D1 DE 69942837 D1 DE69942837 D1 DE 69942837D1 DE 69942837 T DE69942837 T DE 69942837T DE 69942837 T DE69942837 T DE 69942837T DE 69942837 D1 DE69942837 D1 DE 69942837D1
Authority
DE
Germany
Prior art keywords
virus
ligand
gene therapy
geneaving
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942837T
Other languages
English (en)
Inventor
Esther H Chang
Kathleen Pirollo
Liang Xu
William Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
SynerGene Therapeutics Inc
Original Assignee
Georgetown University
SynerGene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, SynerGene Therapeutics Inc filed Critical Georgetown University
Application granted granted Critical
Publication of DE69942837D1 publication Critical patent/DE69942837D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69942837T 1998-11-19 1999-11-19 Systemisches virus/ligand genabgabemittel und gentherapie Expired - Lifetime DE69942837D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10923698P 1998-11-19 1998-11-19
US12833099P 1999-04-08 1999-04-08
PCT/US1999/027365 WO2000029600A1 (en) 1998-11-19 1999-11-19 Systemic viral/ligand gene delivery system and gene therapy

Publications (1)

Publication Number Publication Date
DE69942837D1 true DE69942837D1 (de) 2010-11-18

Family

ID=26806780

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942837T Expired - Lifetime DE69942837D1 (de) 1998-11-19 1999-11-19 Systemisches virus/ligand genabgabemittel und gentherapie

Country Status (10)

Country Link
EP (1) EP1131457B1 (de)
JP (2) JP5448283B2 (de)
CN (1) CN100572542C (de)
AT (1) ATE483816T1 (de)
AU (1) AU1628800A (de)
CA (1) CA2349238A1 (de)
DE (1) DE69942837D1 (de)
HK (1) HK1041498B (de)
PT (1) PT1131457E (de)
WO (1) WO2000029600A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337770A1 (de) * 2003-08-14 2005-03-24 TransMIT Gesellschaft für Technologietransfer mbH Endothelzellspezifisches Gentransfersystem
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
DE69736385T2 (de) * 1996-02-09 2007-08-23 Pi-Wan Cheng Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
EP0927044A4 (de) * 1996-04-16 1999-09-08 Immusol Inc Gerichtete viral vektoren
EP0973926A1 (de) 1997-03-14 2000-01-26 Selective Genetics, Inc. Adenovirale vektoren mit verändertem tropismus

Also Published As

Publication number Publication date
CN1326511A (zh) 2001-12-12
JP2002530086A (ja) 2002-09-17
HK1041498B (zh) 2011-07-29
HK1041498A1 (en) 2002-07-12
PT1131457E (pt) 2010-11-18
AU1628800A (en) 2000-06-05
CA2349238A1 (en) 2000-05-25
WO2000029600A1 (en) 2000-05-25
ATE483816T1 (de) 2010-10-15
JP2010213726A (ja) 2010-09-30
EP1131457B1 (de) 2010-10-06
EP1131457A1 (de) 2001-09-12
JP5448283B2 (ja) 2014-03-19
CN100572542C (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
AU2002305450A1 (en) Proteomimetic compounds and methods
CY1114265T1 (el) Πρωτεϊνη συντηξης αλβουμινης
TR199701071T2 (xx) Aktif madde ulaştırmaya mahsus bileşikler ve terkipler.
CA3033788A1 (en) Nucleic acid products and methods of administration thereof
IL144371A0 (en) Her-2/neu fusion proteins
ATE200105T1 (de) Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
WO2002012341A3 (en) Her-2/neu fusion proteins
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
DE60132190D1 (de) Mutierte version der arginin deiminase
WO2004054607A3 (de) Stabile therapeutische proteine
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
DE69942837D1 (de) Systemisches virus/ligand genabgabemittel und gentherapie
TR200100430T2 (tr) Tyrosine kinase SRC kullanılan angiogenesisin modülasyonu için yararlı metot ve bileşimler.
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
BR0013228A (pt) Método e composições utilizados para modulação de angiogenese usando proteìna quinase raf e ras
WO2002062964A3 (en) Ap1 amine oxidase variants
ATE340260T1 (de) Verfahren zur behandlung von tumoren mittels antiangiogener substanzen
Zhou et al. Research on PEGylation of porcine prothrombin for improving biostability and reducing animal immunogenicity
Alabi et al. Bioreversible anionic cloaking enables intracellular protein delivery with ionizable lipid nanoparticles